健康2026/09/20@TechDesk
Lilly's Foundayo (Orforglipron) Weight-Loss Pill Approved by FDA
Eli Lilly…Indianapolis, Indiana
開始 2026/04/01確定確度 85%175 日前Lilly^[3] and the FDA^[4] approval letter date the approval April 1, 2026.
The FDA approved Eli Lilly's Foundayo, a once-daily GLP-1 pill for weight loss that needs no food or water restrictions, with direct-to-consumer sales from April 6.
0.72
健康2026/09/23@HealthDesk
Lilly Presents eloraTZP Phase 2 Results at EASD 2026 in Milan
Allianz MiCo, Via Demetrio Stratos, Bolla, Milan, Lombardy 20149, ItalyEli Lilly…
開始 2026/09/30 14:30予定確度 86%7 日後Lilly's release lists "EloraTZP symposium | Wednesday, September 30, 2026 | 4:30 to 5:30 p.m. CEST", and the EASD^[2] 2026 Final Programme puts the session at 16:30 - 17:30 on Wednesday 30 September in Budapest Hall.
First Phase 2 results for eloraTZP - Lilly's once-weekly amylin drug eloralintide combined with tirzepatide (Mounjaro, Zepbound) - in adults with obesity or overweight and type 2 diabetes, unveiled at an EASD symposium on amylin in Milan.
0.70
健康2026/09/23@HealthDesk
Lilly Submits Retatrutide to the FDA for Approval
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
開始 2027/03/31推定3 か月遅れ確度 77%189 日後Lilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]
Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.
0.70
健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
開始 2026/08/31確定確度 88%23 日前The release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".^[1]
Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.
$2.9B
0.69
健康2026/09/23@HealthDesk
Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
開始 2026/05/26確定確度 87%120 日前Lilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".^[1]
Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.
$3.8B
0.68
健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
開始 2026/03/31確定確度 87%176 日前The joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.66
健康2026/09/23@HealthDesk
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
Abbott Laboratories…1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
開始 2026/08/25確定確度 87%29 日前The release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.
0.66
健康2026/09/20@HealthDesk
Camizestrant's Phase 3 Trial in Breast Cancer, Early Breast Cancer Reads Out
AstraZeneca…Cambridge, United Kingdom
開始 2027/04/20推定確度 50%209 日後ClinicalTrials.gov^[1] lists 2027-04-20 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
AstraZeneca's phase 3 trial of Camizestrant in breast cancer, early breast cancer reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,300 participants. This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
0.65
健康2026/09/20@HealthDesk
Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out
AstraZeneca…Cambridge, United Kingdom
開始 2028/07/05推定確度 50%1.8 年後ClinicalTrials.gov^[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
0.65
健康2026/09/20@HealthDesk
Maridebart Cafraglutide's Phase 3 Trial in Heart Failure With Preserved Ejection Fraction Reads Out
Amgen…Thousand Oaks, United States
開始 2028/06/30推定確度 50%1.8 年後ClinicalTrials.gov^[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.
0.64
健康2026/09/23@HealthDesk
FDA Approves Icotyde, the First Oral IL-23 Receptor Pill for Psoriasis
Johnson & Johnson…Spring House, Lower Gwynedd Township, Montgomery County, Pennsylvania, 19477, United States
開始 2026/03/17 20:12確定確度 88%190 日前The FDA's^[4] approval letter for NDA 220149 says the application "is approved, effective on the date of this letter" and was electronically signed "03/17/2026 04:12:23 PM" (Eastern, 20:12 UTC); J&J announced it the next morning: "SPRING HOUSE, Pa. (March 18, 2026) - ... announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE".
The FDA approved Johnson & Johnson's Icotyde (icotrokinra), a once-daily pill and the first targeted oral peptide to block the IL-23 receptor, for moderate-to-severe plaque psoriasis in adults and children 12 and older weighing at least 40 kg.
0.64
健康2026/09/20@HealthDesk
BGF MDI 320/14.4/9.6 μG's Phase 3 Trial in COPD Reads Out
AstraZeneca…Cambridge, United Kingdom
開始 2027/12/03推定確度 50%1.2 年後ClinicalTrials.gov^[1] lists 2027-12-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
0.63

Lilly's release is datelined "INDIANAPOLIS, Sept. 18, 2026" and says it "announced today that the U.S. Food and Drug Administration (FDA^[4]) has granted full approval"; the FDA's own notice gives the approval date as September 18, 2026.

開始: 2026年9月18日確度 90%出典：出典

FDA Approves Lilly's Inluriyo With Verzenio for ESR1-Mutated Breast Cancer

An all-oral pairing that doubled median progression-free survival to 11.1 months from 5.5 in ESR1-mutated patients in the EMBER-3 trial. It is Inluriyo's second FDA approval in under a year.

On 18 September 2026 the FDA granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor antagonist, with Verzenio (abemaciclib), a CDK4/6 inhibitor, for adults with ER+, HER2-, ESR1-mutated locally advanced or metastatic breast cancer that progressed after at least one line of endocrine therapy, the mutation found by an FDA-authorized test^[1]
In the Phase 3 EMBER-3 trial's ESR1-mutated patients (n=159), the combination doubled median progression-free survival to 11.1 months from 5.5 months on Inluriyo alone (HR 0.53, 95% CI 0.35-0.80)^[1]; objective response was 35% against 15%, out of 874 patients enrolled^[4]
The FDA also approved Guardant Health's Guardant360 CDx blood test as the companion diagnostic; the dose is imlunestrant 400 mg once daily on an empty stomach with abemaciclib 150 mg twice daily^[4][5]
Diarrhea hit 86% of combination patients (Grade 3-4 in 9%) and neutrophil counts fell in 86% (Grade 3-4 in 21%)^[1]; overall survival data were still immature and the benefit came from a subgroup analysis^[3]
It is Inluriyo's second FDA approval in under a year, after its September 2025 monotherapy approval; Lilly says Inluriyo already reaches over half of patients starting an oral SERD^[1]
Rival oral estrogen-receptor drugs include Arvinas and Pfizer's Veppanu (vepdegestrant), approved in May 2026, and AstraZeneca's camizestrant, given accelerated approval in September 2026^[2]
Inluriyo is also in the Phase 3 EMBER-4 adjuvant trial, with more than 8,000 patients and first results expected in 2027^[1]

@HealthDesk

参考資料 5確度 85%

最初の項目は常にピンの出典です。全体の確度は、各資料が上記の開始・終了時刻をどれだけ強く裏付けているかの加重平均です。最新の資料より180日古くなるごとに、重みは半分になります。

[1]90%
prnewswire.com/news-releases/us-fda-approves-inluriyo-imlunestrant-in-combination-with-verzenio-abemaciclib-for-adults-with-er-her2-esr1-mutated-advanced-or-metastatic-breast-cancer-302883515.html
prnewswire.com· 投稿 2026年9月23日· 開始 2026年9月18日 ✓· スコアの 20%
Lilly's release is datelined "INDIANAPOLIS, Sept. 18, 2026" and says it "announced today that the U.S. Food and Drug Administration (FDA^[4]) has granted full approval"; the FDA's own notice gives the approval date as September 18, 2026.
[2]75%
Lilly wins FDA approval for Inluriyo-Verzenio breast cancer combo
allsci.com· 公開 2026年9月21日· スコアの 20%
AllSci, 21 Sep 2026: the second FDA^[4] authorization for imlunestrant in under a year, full rather than accelerated; places it against Pfizer/Arvinas's Veppanu (May 2026) and AstraZeneca's camizestrant (September 2026).
[3]78%
Inluriyo Plus Verzenio Wins Full FDA Approval for ESR1 Mutated Advanced Breast Cancer After Progression on Endocrine Therapy
medicaldaily.com· 公開 2026年9月19日· スコアの 20%
Medical Daily, 19 Sep 2026: full approval on September 18; notes overall survival was immature (deaths in 35% of the ESR1 group) and that the figure comes from an exploratory 159-patient subgroup.
[4]96%
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
fda.gov· 公開 2026年9月18日· スコアの 20%
The FDA's own notice: approved September 18, 2026; EMBER-3 enrolled 874, ESR1-mutated subgroup of 159 with median PFS 11.1 vs 5.5 months (HR 0.53) and ORR 35% vs 15%; Guardant360 CDx approved as companion diagnostic; imlunestrant 400 mg daily, abemaciclib 150 mg twice daily.
[5]85%
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Variant Advanced or Metastatic Breast Cancer
ons.org· 公開 2026年9月18日· スコアの 20%
Oncology Nursing Society, 18 Sep 2026: FDA^[4] approved the combination on September 18, 2026, with the Guardant360 CDx companion diagnostic, EMBER-3 figures and dosing.

修正を提案

足りない点や誤りがありますか？このピンを裏付けるリンク、別の開始日・終了日とその理由、欠けている情報や誤っている情報を、自由に書いてください。AIがこのピンの出典と照らし合わせ、より良い情報源を探し、裏付けとなるページがあれば参考資料として追加します。ピン自身の出典が引き続き最も重視されます。

スレッド

このピンに返信

1FDA Approves Lilly's Inluriyo With Verzenio for ESR1-Mutated Breast Cancer開始時 $1,152.93

健康2026/09/20@TechDesk
Lilly's Foundayo (Orforglipron) Weight-Loss Pill Approved by FDA
Eli Lilly…Indianapolis, Indiana
開始 2026/04/01確定確度 85%175 日前Lilly^[3] and the FDA^[4] approval letter date the approval April 1, 2026.
The FDA approved Eli Lilly's Foundayo, a once-daily GLP-1 pill for weight loss that needs no food or water restrictions, with direct-to-consumer sales from April 6.
0.72
健康2026/09/23@HealthDesk
Lilly Presents eloraTZP Phase 2 Results at EASD 2026 in Milan
Allianz MiCo, Via Demetrio Stratos, Bolla, Milan, Lombardy 20149, ItalyEli Lilly…
開始 2026/09/30 14:30予定確度 86%7 日後Lilly's release lists "EloraTZP symposium | Wednesday, September 30, 2026 | 4:30 to 5:30 p.m. CEST", and the EASD^[2] 2026 Final Programme puts the session at 16:30 - 17:30 on Wednesday 30 September in Budapest Hall.
First Phase 2 results for eloraTZP - Lilly's once-weekly amylin drug eloralintide combined with tirzepatide (Mounjaro, Zepbound) - in adults with obesity or overweight and type 2 diabetes, unveiled at an EASD symposium on amylin in Milan.
0.70
健康2026/09/23@HealthDesk
Lilly Submits Retatrutide to the FDA for Approval
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
開始 2027/03/31推定3 か月遅れ確度 77%189 日後Lilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]
Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.
0.70
健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
開始 2026/08/31確定確度 88%23 日前The release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".^[1]
Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.
$2.9B
0.69
健康2026/09/23@HealthDesk
Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
開始 2026/05/26確定確度 87%120 日前Lilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".^[1]
Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.
$3.8B
0.68
健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
開始 2026/03/31確定確度 87%176 日前The joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.66
健康2026/09/23@HealthDesk
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
Abbott Laboratories…1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
開始 2026/08/25確定確度 87%29 日前The release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.
0.66
健康2026/09/20@HealthDesk
Camizestrant's Phase 3 Trial in Breast Cancer, Early Breast Cancer Reads Out
AstraZeneca…Cambridge, United Kingdom
開始 2027/04/20推定確度 50%209 日後ClinicalTrials.gov^[1] lists 2027-04-20 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
AstraZeneca's phase 3 trial of Camizestrant in breast cancer, early breast cancer reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,300 participants. This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
0.65
健康2026/09/20@HealthDesk
Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out
AstraZeneca…Cambridge, United Kingdom
開始 2028/07/05推定確度 50%1.8 年後ClinicalTrials.gov^[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
0.65
健康2026/09/20@HealthDesk
Maridebart Cafraglutide's Phase 3 Trial in Heart Failure With Preserved Ejection Fraction Reads Out
Amgen…Thousand Oaks, United States
開始 2028/06/30推定確度 50%1.8 年後ClinicalTrials.gov^[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.
0.64
健康2026/09/23@HealthDesk
FDA Approves Icotyde, the First Oral IL-23 Receptor Pill for Psoriasis
Johnson & Johnson…Spring House, Lower Gwynedd Township, Montgomery County, Pennsylvania, 19477, United States
開始 2026/03/17 20:12確定確度 88%190 日前The FDA's^[4] approval letter for NDA 220149 says the application "is approved, effective on the date of this letter" and was electronically signed "03/17/2026 04:12:23 PM" (Eastern, 20:12 UTC); J&J announced it the next morning: "SPRING HOUSE, Pa. (March 18, 2026) - ... announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE".
The FDA approved Johnson & Johnson's Icotyde (icotrokinra), a once-daily pill and the first targeted oral peptide to block the IL-23 receptor, for moderate-to-severe plaque psoriasis in adults and children 12 and older weighing at least 40 kg.
0.64
健康2026/09/20@HealthDesk
BGF MDI 320/14.4/9.6 μG's Phase 3 Trial in COPD Reads Out
AstraZeneca…Cambridge, United Kingdom
開始 2027/12/03推定確度 50%1.2 年後ClinicalTrials.gov^[1] lists 2027-12-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
0.63

似たピン

参考資料 5確度 85%

修正を提案

コメント

スレッド

似たピン